SAT-3247

AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach.

Satellos Bioscience has dosed the first participant with Duchenne muscular dystrophy (DMD) in its Phase 1b trial of SAT-3247, an oral small molecule drug.

Satellos Bioscience has dosed the first healthy volunteer in a Phase 1 clinical study of SAT-3247, an oral small molecule drug targeting AAK1.